瑞利珠单抗新适应症在华获批，用于视神经脊髓炎谱系疾病

Core Points - The long-acting C5 complement inhibitor, Riluzole injection (trade name: Weili Rui), has been officially approved in China for the treatment of adult patients with AQP4 antibody-positive Neuromyelitis Optica Spectrum Disorder (NMOSD) [1] - The approval is based on positive results from the CHAMPION-NMOSD Phase III clinical trial, which has been published in the Annals of Neurology [1] - NMOSD is a rare, highly disabling autoimmune disease primarily affecting the central nervous system, particularly the spinal cord and optic nerves [1] - Patients with NMOSD often experience unpredictable relapses, which can lead to new or worsening neurological damage, resulting in severe and recurrent neurological deficits or even permanent disability [1] - Riluzole, as a long-acting complement inhibitor, can precisely target complement pathways, providing sustained benefits with a dosing frequency of once every eight weeks, offering a more convenient treatment experience for patients in China [1] Industry Context - Riluzole has also been approved in the United States, European Union, Japan, and other regions for the treatment of AQP4 antibody-positive adult NMOSD patients, and has received multiple indications in various countries [2]